remodeling and its severity have been associated with poor patient outcomes. 8, 9 In contrast, improvement of LV remodeling indices during treatment for HF is strongly associated with improved survival. 8 Accordingly, it is important to gain a better understanding of factors that predict LV remodeling and its reversal to determine how to best monitor such remodeling. One method for studying LV remodeling is through the measurement of circulating biomarkers such as natriuretic peptides (NP), which may be useful as a noninvasive surrogate measure of cardiac structure and function in patients with HF with reduced ejection fraction (HFrEF). 10 Beyond predicting less (and reversed) LV remodeling, lower N-terminal pro-B-type NP (NT-proBNP) concentrations have been associated with positive patient outcomes. [11] [12] [13] Other biomarkers may similarly inform LV remodeling when measured serially over time. 14 In addition to informing the underlying biology of HF, measurement of LV remodeling and circulating HF biomarkers may also provide researchers with an improved mechanistic understanding of the clinical responses associated with HF therapies. 15 In this regard, such assessments may be helpful for better understanding regarding the mechanism of action of sacubitril/valsartan, a novel angiotensin receptorneprilysin inhibitor (ARNI) whose actions include inhibition of neprilysin, a ubiquitous enzyme involved in the degradation of numerous beneficial vasoactive peptides including several measurable and prognostic biomarkers. 16 For example, treatment with sacubitril/ valsartan led to an increase in BNP concentrations in the Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF; NCT01035255) study. In contrast, NT-proBNP concentrations fell after initiation of sacubitril/ valsartan; this is in part because this peptide is not a substrate for neprilysin 17 but also presumably because sacubitril/valsartan led to improvements in LV remodeling and/or cardiac performance. Although some understanding exists regarding the effects of sacubitril/valsartan on biomarkers of HF, much remains uncertain. This may be in part due to the fact sacubitril/valsartan moved directly from Phase 1 to Phase 3 testing in HFrEF, bypassing Phase 2 trials, where mechanistic end points are typical. Accordingly, correlation of biomarker changes under treatment with sacubitril/valsartan with specific physiologic measurements, such as LV remodeling, has not been performed. As well, acute changes in NT-proBNP and BNP concentrations after sacubitril/valsartan initiation and during uptitration have not been determined because of the limited blood sampling in the PARADIGM-HF trial during this period; although longer-term followup sampling was present in PARADIGM-HF, durability of such shortterm changes across treatment was less clearly defined. It is also uncertain whether neprilysin inhibition affects different BNP assays from those used in the trial. It may also be helpful to measure other biomarkers that were not studied in the PARADIGM-HF trial to inform the mechanism of action leading to the beneficial effects of sacubitril/ valsartan. Thus, this study was designed to (1) correlate efficacy biomarker changes with cardiac remodeling parameters, CV outcomes, and patient-reported outcome data and (2) determine short-and long-term changes in concentrations of biomarkers related to the mechanism of action and effects of sacubitril/valsartan therapy over a period of 12 months.
Methods

Study organization
The PROVE-HF trial was conceived of, designed, proposed, and developed by the Study Steering Committee in conjunction with the sponsor (Novartis Pharmaceuticals Corporation). Study investigators received grant support from the sponsor for their participation in this research project.
As the prescription of medication in this trial is by standard of care based on the approved indications for sacubitril/valsartan, no data safety monitoring board or end point adjudication committee will be used.
Sources of funding
This study is sponsored by Novartis Pharmaceuticals Corporation. Medical writing assistance for this manuscript was provided by Marcel Kuttab, PharmD, of Oxford PharmaGenesis Inc, Newtown, PA, and was also funded by Novartis Pharmaceuticals Corporation, East Hanover, NJ. The authors contributed significantly to the drafting, editing, and revision of the manuscript and are solely responsible for the design and conduct of this study, all study analyses, the drafting and editing of the paper, and its final contents. The authors received no financial support or other form of compensation related to the development of this manuscript.
Patient eligibility and enrollment
The Prospective Study of Biomarkers, Symptom Improvement, and Ventricular Remodeling During Sacubitril/Valsartan Therapy for Heart Failure (PROVE-HF) is a Phase IV, 52-week, multicenter, open-label, single-arm trial (Figure) of patients initiated on sacubitril/valsartan per the standard of care. The trial protocol, written informed consent form, consent form updates, and subject recruitment procedures have been approved by the institutional review board. During screening, eligibility requirements were assessed and confirmed (Table I) . Notably, patients must be aged ≥18 years, have NYHA functional class II-IV with LV ejection fraction (LVEF) ≤40%, be naive to and eligible for onlabel sacubitril/valsartan treatment per the standard of care with no contraindications to therapy, and have no history of angioedema or malignancy within 1 year. Blood and urine samples were also collected during screening for the safety assessment. Patients previously receiving angiotensin-converting enzyme inhibitor (ACEI) therapy require a 36-hour washout period before initiation of sacubitril/valsartan to reduce the risk of angioedema. At the time of manuscript submission, 795 patients have been enrolled in the trial.
The treatment period begins on day 1 with initial dosing of sacubitril/valsartan, followed by uptitration every 2 to 4 weeks, according to the United States prescribing information, to the target dose of 97/103 mg twice daily. The 3 doses of sacubitril/valsartan available throughout the study are 24/26 mg (dose level 1), 49/51 mg (dose Level 2), and 97/103 mg (dose Level 3), each taken by mouth twice daily.
Dose adjustment and study procedures
Doses may be adjusted based on overall safety and tolerability (Table II) . If necessary, dose adjustments or elimination of concomitant medications is made to alleviate adverse effects. If adverse effects are not alleviated or it is not possible to adjust concomitant medications, the study treatment may be downtitrated by 1 dose level-or, at the lowest dose, temporarily withdrawn-for 1 to 4 weeks. The patient may then be reassessed and the study treatment further downtitrated every 1 to 4 weeks until the patient is deemed stable. Once stability is achieved, the patient is rechallenged with uptitration to the target dose. If the patient discontinues the study medication, the patient is advised to return to the clinic for an end-of-study visit.
Patients undergo treatment for 12 months with visits occurring every 2 weeks until day 60 (visit 6). Thereafter, the next visit occurs at day 90 (visit 7), with visits occurring every 90 days until study completion at day 365 (visit 10). This schedule allows for evaluation of the short-term effects of sacubitril/valsartan during initiation and titration. PROVE-HF is registered at ClinicalTrials.gov: NCT02887183. The study protocol was approved by relevant institutional review boards, and all subjects were required to sign informed consent prior to enrollment.
Biomarkers
Blood and urine samples are collected throughout the study to measure numerous biomarkers. Stable biomarkers, including NT-proBNP, do not require specialized equipment and can be collected at all study sites. Another stable marker to be measured is urinary cyclic guanosine monophosphate, the downstream second messenger from binding of atrial natriuretic peptide (ANP) and BNP to the NP receptor. 16 Concentrations of the interleukin receptor family member soluble suppressor of tumorgenicity 2 and high-sensitivity troponin may also be measured. These biomarkers have been demonstrated to be indicative of cardiomyocyte stress, necrosis, and fibrosis, with each being a strong prognostic indicator in chronic HFrEF 18, 19 and known to be improved by treatment with sacubitril/valsartan. 17, 20 Labile biomarkers requiring special samples handling are measured in a subset of study sites. Measured labile biomarkers may include, but are not limited to, ANP and BNP from 3 separate methods that use different antibody pairs. Given the short half-life of ANP and modest in vitro instability of BNP (consequent in part to effects of proteases), both ANP and BNP samples must be collected using tubes with protease inhibitors to improve their stability (Beckman Coulter P-100 tubes; Beckman Coulter, Pasadena, CA) so that their concentrations may be accurately measured. Other labile biomarkers that may be measured include the inactive precursor peptide proBNP and adrenomedullin, an endogenous vasodilator that has been shown to reduce myocyte hypertrophy, fibroblast proliferation, collagen synthesis, and aldosterone secretion and may be affected by sacubitril/valsartan. 16 Biomarkers evaluated may change during the study as new or more relevant biomarkers are determined (Table III) .
Study end points
The study end points and statistical methods (Table IV) were selected to further characterize the known effects of sacubitril/valsartan on biomarker concentrations and to more explicitly monitor the biomarker profile of patients over time. Thus, the primary objective of this study is to examine the association between the changes in concentration of NTproBNP and cardiac remodeling, assessed by echocardiographic parameters of volume, from baseline to 1 year. Similarly, secondary objectives included examining the association between the changes in concentration of NT-proBNP and cardiac remodeling from baseline to 6 months, as well as changes in concentration of NT-proBNP and patient-reported outcomes assessed by the Kansas City Cardiomyopathy Questionnaire (KCCQ-23) from baseline to 1 year.
Exploratory objectives were selected to expand on the effects of sacubitril/valsartan on biomarkers other than NPs and to examine the association between the change in efficacy biomarkers and remodeling indices with patient outcomes. CV event analyses of interest include all deaths (CV vs non-CV, sudden vs nonsudden), resuscitated sudden death, HF hospitalization, and worsening HF, defined as (1) new or progressive symptoms or signs of decompensated HF and (2) unplanned intensification of oral or intravenous decongestive therapy with diuretic agents. To address the uncertainty in understanding whether sacubitril/ valsartan affects major representatives of available BNP assays similarly, the effects of sacubitril/valsartan on BNP, as measured by 3 assay types commonly used, are examined in a subset of study patients (n = 180). In the same subset (n = 180), labile biomarkers are also examined as a function of change in echocardiographic variables.
These end points are also examined for subgroups of interest to determine whether they are similarly influenced by sacubitril/valsartan therapy. Subgroups represent patients for whom data on sacubitril/ valsartan are lacking, including (1) patients with HFrEF and "low" NTproBNP concentration (b600 pg/mL if not hospitalized or b400 pg/mL if hospitalized) or "low" BNP concentration (b150 pg/mL if not hospitalized or b100 pg/mL if hospitalized) at baseline 21 ; (2) patients with newonset HF and/or who are renin-angiotensin-aldosterone system (RAAS)-inhibitor-therapy naive 22 ; and (3) patients receiving suboptimal doses of sacubitril/valsartan. 23 Changes in cardiac remodeling are determined by using echocardiographic assessments of LV mass, LV volume, and diastolic function (Table V) . 10 These changes are evaluated from baseline to 12 months, as well as from baseline to 6 months. As noted, various biomarkers are examined to provide useful information to understand the mechanism of action or mechanism of benefit of sacubitril/valsartan (Table III) .
As each of these biomarkers has been linked to remodeling parameters, 10,14,24-28 changes in each biomarker are correlated with changes in echocardiographic measures of remodeling. Clinical patient assessments are performed to provide context for biomarker and echocardiographic results. CV events, including death (CV vs non-CV, sudden vs nonsudden), resuscitated sudden death, HF hospitalization, and worsening HF (WHF), are assessed. In addition, NYHA classification is determined. Signs and symptoms of HF are also assessed, including dyspnea, fatigue, edema, orthopnea, rales, jugular venous distension, and heart sounds. Health status and health-related quality of life are measured by use of the KCCQ-23. 29 The safety of sacubitril/valsartan is examined relative to its effects on blood pressure, renal function, and risk of angioedema. Safety assessments consist of monitoring and recording all adverse events (AEs) and serious adverse events (SAEs), as well as evaluating hematology and blood chemistry, vital signs, height and body weight, and renal function, as assessed by serum creatinine and urine samples to detect proteinuria, hematuria, and glycosuria. Safety is also assessed by patient physical examination and both serum and urine pregnancy tests. The incidence of AEs is reported, including worsening renal function (defined as an increase in serum creatinine ≥0.5 mg/dL and a decrease in estimated glomerular filtration rate [eGFR] ≥25%), symptomatic hypotension, hyperkalemia (defined as potassium levels N5.5 mEq/L), and angioedema.
Statistical analyses and powering
Pearson correlation coefficients and the corresponding 2-sided 95% CIs and P values will be calculated to examine the association between change in log-transformed NT-proBNP levels and each structural cardiac measurement (LV end-systolic volume index, LV end-diastolic volume index, LVEF, left atrial volume index, and the LV transmitral early diastolic filling velocity/LV early diastolic myocardial velocity [E/e']) from baseline through 1 year. The analyses will be repeated from baseline to 6 months. Sensitivity analyses will be performed using the last observation carried forward method used to impute missing data at 1 year.
An analysis of variance will be conducted to compare the mean change in the KCCQ-23 clinical summary scores between the groups of patients with NT-proBNP b1000 pg/mL and ≥1000 pg/mL at month 12.
It is likely that groups defined in this way will be different with respect to characteristics that are also associated with the KCCQ-23 clinical summary scores, including age (b75 years vs ≥75 years), LVEF (≤ median vs N median), eGFR (≤ median vs N median), primary HF etiology (ischemic vs nonischemic), and presence of atrial fibrillation at baseline, as well as the standardized β-blocker dose achieved at Month 12.
11,12 Multivariable regression will be used to compare the mean change in KCCQ-23 clinical summary score by NT-proBNP group, accounting for variability in individual patient characteristics by including them as covariates in the model. In addition, an optional sensitivity analysis using propensity score stratification (or matching) may be performed to provide an estimate of the differences by NT-proBNP group between patients who are more similar with respect to baseline characteristics, as well as the standardized β-blocker dose achieved at month 12.
Pearson correlation coefficients and their 2-sided 95% CIs will be used to examine the association between both concentration value and change from baseline in concentration of the more stable biomarkers reflecting mechanism of action of sacubitril/valsartan and/or HF prognosis, and echocardiographic variables will be calculated using values from the visits at 3 months, 6 months, and 1 year. These statistical measures will also be used to examine the association between the total number of CV events and the changes from baseline in biomarkers, and the changes from baseline in echocardiographic variables at 1 year will be calculated.
In the ProBNP Outpatient Tailored Chronic HF therapy (PROTECT; NCT00351390) trial, patients who achieved NT-proBNP concentrations b1000 pg/mL had the lowest frequency of CV events compared with those with higher NT-proBNP concentrations (P b .001 for trend).
11 Accordingly, the total number of CV events during the 12-month followup period will be summarized for patients achieving NT-proBNP b1000 pg/mL at any time during months 1-3 of the study, at any time during months 1-6 of the study, and at all assessments. The time to reach NT-proBNP b1000 pg/mL for patients with a baseline value ≥1000 pg/mL, as well as the time spent with an NT-proBNP b1000 pg/mL during 1 year of follow-up, will be calculated for patients with and without a CV event. Time in response will be estimated using NT-proBNP values assessed during follow-up, either by assuming no change in value between assessments (ie, assuming a piecewiseconstant concentration profile) or by using linear interpolation between assessments to estimate values and response status. Similar analyses will be done in the subset of patients (n = 180) for whom labile mechanism of action biomarkers are collected. Separate statistical analyses will also be performed for patient subgroups of interest, representing patients for whom data on sacubitril/valsartan are lacking.
The correlation coefficient will be estimated with a precision (halfwidth of the CI) of at least 0.15 for a 2-sided 95% CI in the intended subgroups of interest. The smallest subgroup of interest is estimated to be 20% of the overall study population. Assuming the population correlation coefficient of −0.35 10 for the overall study sample and within each subgroup, the smallest sample size that would yield a precision of at least 0.15 for the estimated correlation, the coefficient would be • Postural symptoms or any conditions that preclude continuation according to the investigator's judgment n = 133. Accounting for assumed 20% dropout rate, 166 patients would be required. If n = 166 for the smallest subgroup of interest, an overall sample size of 830 patients would be required to enroll in this study.
Discussion
The principal aims of this study are (1) to correlate efficacy biomarker changes with cardiac remodeling parameters, CV outcomes, and patient-reported outcome data and (2) to determine short-and longterm changes in concentrations of biomarkers related to potential mechanism of action and effects of sacubitril/valsartan therapy for 12 months. Although PARADIGM-HF demonstrated the efficacy of sacubitril/valsartan in reducing the risk of the composite outcome of CV death or first hospitalization for worsening HF compared with treatment with enalapril, questions remain as to the biologic effects of sacubitril/valsartan therapy. Specifically, no data are available regarding ventricular remodeling, and other mechanisms of benefit are unclear, including reduction of myocardial injury and fibrosis; nonetheless, given that the benefit of sacubitril/valsartan appeared to be related to improvement in rates of progressive pump failure or sudden cardiac death, it is reasonable to hypothesize significant reverse remodeling related to ARNI therapy.
Although currently embedded in clinical practice guidelines for diagnosis and prognosis of HF, 30 use of biomarkers has gradually increased in clinical trials of novel HF therapies. Studying biomarkers in patients receiving new HF therapies may lead to important findings regarding mechanism of action and mechanism of benefit, and in turn may provide useful information for clinical decision making after a therapy is approved for use. In this regard, serial measurement of several biomarkers with differing biology and prognostic meaning may provide insight regarding the effects of sacubitril/valsartan. Furthermore, securing better understanding of how such biomarkers change over time during treatment with sacubitril/valsartain may provide information on how to best monitor therapy for patients receiving this drug; specifically, if biomarker concentrations can be correlated with changes in cardiac remodeling and patient outcomes, then it may be possible to use these measures to monitor the efficacy of sacubitril/valsartan over time in individuals. In the PARADIGM-HF study, the limited blood sampling was insufficient for the assessment of the short-and long-term effects of sacubitril/valsartan on biomarker concentrations. In this study, multiple sequential assessments throughout the initiation and titration of sacubitril/valsartan will allow for observations on changes in biomarker concentrations over time. Such short-term efficacy biomarker changes may be used for the optimal titration of ARNI therapy, and long-term efficacy biomarker changes may provide insight regarding the clinical benefits that patients receive. In addition, it is uncertain whether various BNP assays would provide consistent results in the context of neprilysin inhibition because only 1 type of BNP assay was assessed in the PARADIGM-HF trial. To provide information regarding assay selection for the measurement of BNP concentrations in patients with HF receiving sacubitril/valsartan, 3 assay types are used to measure BNP concentrations in this trial.
In addition to biomarkers and echocardiographic changes, the PROVE-HF trial includes assessments of both patient-reported outcomes and clinical events. Patient-reported outcome data are useful in providing a clinical context to understand the mechanism of benefit of sacubitril/valsartan; therefore, correlations between the changes in biomarker concentrations with specific outcomes will be examined. Although data regarding patient-reported outcomes are available from PARADIGM-HF, baseline KCCQ-23 assessments were completed after the run-in phases, which may not accurately represent true baseline values. The varying inclusion criteria for PROVE-HF (including enrollment of patients more typical of "real-world" practice, patients with de novo HF, and those with lower natriuretic peptide concentrations) and baseline assessment of KCCQ-23 prior to initiating ARNI therapy will extend the understanding of how sacubitril/valsartan may impact quality of life. Furthermore, clinical outcomes including death, worsening HF, and hospitalizations for HF will be evaluated. Although mortality and hospitalization have commonly been studied in HF clinical trials, WHF has become recognized as a signal of HF deterioration and poor prognosis. 31 An analysis of data from the PROTECT study found that ambulatory patients with WHF had a significantly higher rate of HF hospitalization compared with patients without WHF (53% vs 1%; P b .001).
31
These results highlight the importance of understanding the effect of sacubitril/valsartan on the development of WHF.
Clinical implications
Through its design, PROVE-HF will allow for assessment of several important topics not yet addressed in present clinical trials. Study investigators will be encouraged to titrate therapy as per the approved dosing, aiming for the doses achieved in PARADIGM-HF; rates of target dose achievement will be tracked. However, in contrast to PARADIGM-HF, patients will not be removed if they cannot tolerate maximum dose sacubitril/valsartan. Thus, a unique aspect of PROVE-HF is that it will be the first large-scale study of ambulatory patients with HFrEF in which low-dose (24/26 mg) sacubitril/valsartan will be used. Although anecdotal experience suggests that this dose is commonly used in general practice, few data are available regarding potential impact on biomarkers, LV structure/function, patient-reported outcomes, as well as safety (in particular regarding hypotension). Additionally, as the study will be performed in North America, the percentage of African American patients will be higher than PARADIGM-HF; as black patients are at higher risk for angioedema under treatment with neprilysin inhibitors, 32 we will examine this question in a larger percentage of patients than was possible in PARADIGM-HF. Although assessing safety is not a primary goal of this study, safety findingsparticularly with respect to blood pressure, renal function, and angioedema-should expand the knowledge base for sacubitril/ valsartan. As a result of the enrollment inclusion criteria for PARADIGM-HF, the effects of sacubitril/valsartan on biomarker concentrations also remain uncertain for patients with NT-proBNP b600 pg/mL or BNP b150 pg/mL (b400 pg/mL or b100 pg/mL if hospitalized, respectively) and for patients naive to HF therapy. To determine whether biomarkers and echo parameters for these patient populations are similarly affected by sacubitril/valsartan therapy, the results from these subgroups of interest will be analyzed separately.
Although providing important information, the limitations of the PROVE-HF study will need to be considered when interpreting its results. The nonrandomized, noncomparative study design limits the internal validity of this study; however, the strong recommendation for the use of sacubitril/valsartan (class of recommendation, I; level of evidence, B-R) in the 2017 publication of the focused update to the American College of Cardiology/American Heart Association/Heart Failure Association of America guideline for the management of HF makes a comparison arm inappropriate for a study of 1-year duration because it would prevent patients in the control arm from having access to lifesaving therapy. 30 Stated differently, it is arguable that long-term randomization to potentially inferior therapy versus ARNI is not ethical. Given the design of PARADIGM-HF, one might accept a short-term randomization to ACEI or angiotensin receptor blocker (ARB) followed by crossover to sacubitril/valsartan, although it is unclear if such a design would permit conclusive results regarding remodeling. Another limitation is that biomarkers are an indirect measure of drug effect and are not a perfect surrogate measure for clinical outcomes; however, they remain a reliable and accessible measure to monitor patients. 30, 33 Certain biomarkers may be useful to predict HF prognosis and LV remodeling; however, further evaluation of existing and novel markers to guide therapy is needed. 33 Lastly, other randomized studies are ongoing regarding use of sacubitril/valsartan in patients with acute HF as well as end-stage HF. Although many of these include biomarkers in their design, only PROVE-HF will correlate biomarker changes with cardiac remodeling parameters. PROVE-HF will therefore address a population of patients relevant to current approved usage for sacubitril/valsartan and provide important mechanistic understanding relative to the outcome improvement seen in PARADIGM-HF.
Conclusions
The 2017 American College of Cardiology/American Heart Association/ Heart Failure Association of America guideline update recommended the use of an ARNI/ACEI/ARB in conjunction with standard therapy for patients with chronic HFrEF to reduce morbidity and mortality. 30 Although the use of sacubitril/valsartan is increasing, limited guidance has been provided regarding the initiation and monitoring of therapy. This Phase IV, 52-week, multicenter, open-label, single-arm trial will assess changes in cardiac remodeling, biomarker concentrations, and patient outcomes in patients taking sacubitril/valsartan. The understanding gained from this trial will therefore help to establish a mechanistic understanding of benefits from ARNI therapy, generate useful data to support clinical decision making when initiating and titrating the drug, and fill in needed data regarding populations of patients not well represented in the PARADIGM-HF trial. 
Secondary objectives
• Association between changes in concentration of NT-proBNP and structural cardiac measurements from baseline to 6 m
• Pearson correlation coefficient and its 2-sided 95% CI from baseline to 6 m ○ Similar calculations for subgroups⁎ • Association between the change in NT-proBNP concentrations and patient-reported outcomes from the KCCQ-23 scores from baseline to 1 y
• Analysis of variance at 1 y to compare the mean change in KCCQ-23 summary score between subjects with NT-proBNP b1000 pg/mL and NT-proBNP ≥1000 pg/mL ○ Propensity-score adjustments will be used to account for between-group differences in baseline covariate data, attributed to lack of randomization
Exploratory objectives
• Changes in concentration of other biomarkers related to efficacy, HF prognosis, or MOA, collected for the entire patient population from baseline to each interim study visit, throughout 1 y of management, and examined as a function of changes in echocardiographic parameters
• Pearson correlation coefficient and its 2-sided 95% CI from baseline to 1 y
• Association between change in efficacy biomarkers and echocardiographic remodeling indices with CV events following sacubitril/valsartan initiation and uptitration, from baseline to 1 y, including: ○ All deaths ▪ CV vs non-CV ▪ Sudden vs nonsudden ○ Resuscitated sudden death ○ HF hospitalization ○ Worsening HF
• Pearson correlation coefficient and its 2-sided 95% CI from baseline to 1 y • Total CV event rate for subjects with NT-proBNP b1000 pg/mL at each time point • Time to NT-proBNP value b1000 pg/mL ("time to response") for subjects with baseline value ≥1000 pg/mL, as well as time spent with NT-proBNP b1000 pg/mL ("time in response") during 1 y of follow-up, calculated for subjects with and without a CV event
• Effects of sacubitril/valsartan on concentrations of BNP, determined by several assays used in clinical practice, in a subset of patients (n = 300) †
• Changes in median concentration of each BNP assay from baseline to each interim study visit and from the previous to current interim visit • Changes in concentration of labile biomarkers thought to reflect the MOA of sacubitril/valsartan, from baseline to 1 y, examined as a function of change in echocardiographic variables (n = 300)
• Pearson correlation coefficient and its 2-sided 95% CI from baseline to 1 y MOA, Mechanism of action. ⁎ Subgroups of interest include patients with HFrEF and "low" NT-proBNP concentration (b600 pg/mL if not hospitalized; b400 pg/mL if hospitalized) at baseline; patients with newonset HF and/or are RAAS-inhibitor-therapy naive; patients with suboptimal doses of sacubitril/valsartan; and patients with NT-proBNP levels b1000 pg/mL or ≥1000 pg/mL at the same timepoints.
† Will be repeated for subgroups, including patients with new-onset HF and/or are RAAS-inhibitor-therapy naive, patients with BNP levels b150 pg/mL (or b100 pg/mL if hospitalized within 1 year), and patients at the maximum dose of sacubitril/valsartan. 
